<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106742</url>
  </required_header>
  <id_info>
    <org_study_id>AbM2009-IBD</org_study_id>
    <nct_id>NCT01106742</nct_id>
  </id_info>
  <brief_title>Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)</brief_title>
  <official_title>Potential Anti-inflammatory Effect of Mushroom Extract From Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the anti-inflammatory and stabilising effect of the AbM, (Agaricus Blazei Murill)
      based mushroom extract AndoSanTM on cytokine release in blood in vivo and ex vivo in healthy
      volunteers after 12 days consumption, the aim in this study is to investigate whether same
      effect is valid in patients with IBD (inflammatory bowel disease). In addition, calprotectin
      an abundant cytosolic protein in neutrophils and a surrogate marker for degree of intestinal
      inflammation will be measured in blood and feces of these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ultimate goal is to see whether the ABM can be used as additional treatment of IBD.</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>AndoSan, UC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AndoSan as a supplement to 10 UC patents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AndoSan, CD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AndoSan as a supplement to 10 CD patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AndoSan</intervention_name>
    <description>AndoSan, 20mlx3, 12 days</description>
    <arm_group_label>AndoSan, UC</arm_group_label>
    <arm_group_label>AndoSan, CD</arm_group_label>
    <other_name>Agaricus blazei Murill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate disease activity

        Exclusion Criteria:

          -  No use of Imurel (Azathioprin) or anti-TNF treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oslo University Hospital, Department of Surgery</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>MD. Dag T. FÃ¸rland</name_title>
    <organization>Ullevaal University Hospital</organization>
  </responsible_party>
  <keyword>Inflammatory</keyword>
  <keyword>AbM</keyword>
  <keyword>IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

